Wuxi Biologics (Cayman) (2269N) Stock Statistics & Valuation Metrics

Wuxi Biologics (Cayman) has a market cap or net worth of $434.39B. The enterprise value is $140.19K.

Wuxi Biologics (Cayman) has 4,154,734,000 shares outstanding. The number of shares has decreased by -2.65% in one year.

Wuxi Biologics (Cayman)’s return on equity (ROE) is 0.10 and return on invested capital (ROIC) is 9.26%.

The current PE Ratio of Wuxi Biologics (Cayman) is 34.9. Wuxi Biologics (Cayman)’s PEG ratio is 0.59.

In the last 12 months, Wuxi Biologics (Cayman) had revenue of 21.79B and earned 4.91B in profits. Earnings per share was 1.16.

In the last 12 months, operating cash flow was 4.60B and capital expenditures -1.81B, giving a free cash flow of 2.79B billion.

Wuxi Biologics (Cayman) pays an annual dividend of ―, resulting in a dividend yield of ―

Wuxi Biologics (Cayman) upcoming earnings date is Mar 23, 2027, TBA (Confirmed).

Wuxi Biologics (Cayman) as a current ratio of 3.14, with Debt / Equity ratio of 5.67%

In the past 12 months, Wuxi Biologics (Cayman) has paid 1.52B in taxes.

Wuxi Biologics (Cayman) EV to EBITDA ratio is 14.11, with an EV/FCF ratio of 39.95.

Wuxi Biologics (Cayman) has $13.04B in cash and marketable securities with $2.73B in debt, giving a net cash position of $10.31B billion.

Gross margin is 47.47%, with operating margin of 30.47%, and net profit margin of 22.53%.

The average price target for Wuxi Biologics (Cayman) is $124.61, which is 11.43% higher than the current price. The consensus rating is Strong Buy